Sugi Predict

Sugi Predict / Compounds / Biphenyl

Biphenyl

Biphenyl

SCHEMBL9308

c1ccc(-c2ccccc2)cc1.c1nnn[nH]1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.43
▸ AKT1 P31749 1/20 0.41
▸ AKT2 P31751 1/20 0.41
▸ NOTUM Q6P988 1/20 0.39
▸ ATM Q13315 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ CYP3A4 P08684 3/20 0.35
▸ IDO1 P14902 1/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ NFKB1 P19838 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrazole SCHEMBL29023855 0.98 ALDH1A1 (0.41) ALDH1A1AKT1AKT2NOTUMATM
Biphenyl SCHEMBL1627148 0.98 ALDH1A1 (0.41) ALDH1A1AKT1AKT2NOTUMATM
Biphenyl SCHEMBL27802159 0.98 ALDH1A1 (0.41) ALDH1A1AKT1AKT2NOTUMATM
Biphenyl SCHEMBL9158420 0.98 ALDH1A1 (0.41) ALDH1A1AKT1AKT2NOTUMATM
Biphenyl SCHEMBL28359469 0.94 ALDH1A1 (0.38) ALDH1A1AKT1AKT2NOTUMATM
Biphenyl SCHEMBL28349299 0.94 AKT2 (0.38) ALDH1A1AKT1AKT2NOTUMATM
Biphenyl SCHEMBL27894946 0.92 AKT1 (0.36) ALDH1A1AKT1AKT2NOTUMATM
Biphenyl-4-Amine SCHEMBL28165279 0.88 HSD17B10 (0.56) ALDH1A1ATMALOX15CYP3A4RAB9A
Biphenyl SCHEMBL28518040 0.88 SMN1; SMN2 (0.42) ALDH1A1AKT1AKT2ALOX15SMN1; SMN2
Tetrazole SCHEMBL28320883 0.88 NPC1 (0.43) ALDH1A1RAB9ANPC1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109553605-B Pyrazole amide compound containing tetrazole biphenyl structure and preparation method and application thereof 南通大学 2021-03-02 — — CN claimed
EP-3669019-A1 METHODS AND KITS FOR DETECTING ANTIBIOTIC-INACTIVATING FACTORS University of Louisville Research Foundation, Inc. (US) 2020-06-24 — — EP claimed
US-20200172953-A1 METHODS AND KITS FOR DETECTING ANTIBIOTIC-INACTIVATING FACTORS UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. 2020-06-04 — — US claimed
CN-110907567-A N-nitrosamine extraction, separation and detection method 上海市食品药品检验所 2020-03-24 — — CN claimed
CN-106946856-B Pyrazole oxime derivative containing tetrazole biphenyl structure and preparation method and application thereof 南通大学 2020-02-14 — — CN claimed
CN-109081833-A A kind of preparation method of olmesartan medoxomil intermediate 廊坊市泽康医药科技有限公司 2018-12-25 — — CN claimed
CN-102491971-B Chiral [(4- methyl-2-propyl -1H- benzimidazole -6- amide) -1- base] methyl biphenyl class compound and its production and use 北京理工大学 2017-03-01 — — CN claimed
CN-105481842-A Method for preparing olmesartan medoxomil JIANGSU ZHONGBANG PHARMACEUTICAL CO LTD 2016-04-13 — — CN claimed
CN-101774975-B Ionic liquid catalysis ring-closure reaction method INST PROCESS ENG CAS 2012-11-28 — — CN claimed
CN-102491971-A Chiral ((4-methyl-2-propyl-1H-benzimidazole-6-amide)-1-radical) methyl diphenyl compound, as well as preparation method and application thereof BEIJING INST TECHNOLOGY 2012-06-13 — — CN claimed
US-6610682-B2 Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier SANKYO COMPANY, LIMITED (JP) 2003-08-26 — — US claimed
EP-0734398-B1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2002-02-27 — — EP claimed
US-20020013308-A1 Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier SANKYO COMPANY LIMITED (JP) 2002-01-31 — — US claimed
EP-0842424-B1 PROCESS FOR DETERMINING THE EFFECTIVENESS AND TOLERANCE OF A XENOGENIC SUBSTANCE ADMINISTERED TO AN ORGANISM LAUK CHRISTIANE (DE) 1999-11-03 — — EP claimed
CN-1230122-A pharmaceutical composition SANKYO CO (JP) 1999-09-29 — — CN claimed
EP-0930076-A1 MEDICINAL COMPOSITIONS SANKYO COMPANY LIMITED (JP) 1999-07-21 — — EP claimed
US-5773512-A Compounds and methods SMITHKLINE BEECHAM CORP. (US) 1998-06-30 — — US claimed
EP-0734398-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 1997-04-16 — — EP claimed
EP-0734398-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1996-10-02 — — EP claimed
WO-1995016712-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1995-06-22 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013308-A1 Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier AGTR1, AGTR2, ACE ALDH1A1 1200/4885AKT1 2284/4885AKT2 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.